

Structural Variant Detection Tools Struggle with Whole Exome Sequencing (WES) Data

Lokesh Pugalenthi*, Rahul Nanduri*, Raymond Hong*, Rohit K. Prasad†, Dhivya Arasappan†, Jeanne Kowalski-Muegge‡ * Undergrad Research Assistant, College of Natural Sciences, University of Texas at Austin; †Faculty Collaborator, College of Natural Sciences, University of Texas at Austin; ‡ Faculty Collaborator, LiveSTRONG Cancer Institute, Dell Medical School, University of Texas at Austin

Detecting Large Variants in Multiple Myeloma can personalize treatment

- Detecting SVs can lead to more personalised, • Whole Exome Sequencing (WES) provides a snapshot of affordable cancer treatment by predicting antigens the sample's exonic regions (exome). specific to the SVs present in the patient's cancer • By comparing this to a typical exome, we can identify cells (neoantigen).
- structural variants (SVs) in the sample.
- These SVs may play a role in the development of diseases such as multiple myeloma (MM).




Figure 1: The methodology to Whole Exome Sequencing; Genomic DNA is fragmented and only regions that hybridize to the capture array (exons) are isolated and sequenced, providing a view of the exome

Tools' output vary in SV type & length

Structural variants are alterations to the genome typically spanning more than a few hundred base pairs. The 6 tools benchmarked detected different types of SVs of different lengths.





Figure 3: Grouped box plot comparing the length (bp) of the structural variants detected by each tool. Note y-axis is log transformed.



Tool

- As WES is much cheaper than Whole genome sequencing (WGS), effective SV detection on WES data would drastically reduce the costs of detecting a patient's novel cancer-causing SVs
- However, as most SV detection tools are designed for WGS data, it's unclear how well they work with WES data.
- To this end, we benchmarked SV detection tools on 71 MM WES cell lines.

Because these are established cell lines, we have 59 experimentally determined SVs that we expect to see in each cell-line.

We first computed recall of these SVs at the chromosomal level. SvABA and Delly had the best recall rates (78% and 28%) respectively).





Figure 4: Contrasting tool recall rates at the chromosomal (indicated by blue) and coordinate level (indicated by orange). SvABA's unfiltered output has best recall of experimentally determined SVs (19.5%)

Overlapping SV output

As the tools' output had poor recall and little overlap, we ca be most confident SVs detected by m than one tool.

We characterised the cell-lines with 5783 S found by 3 tools w/ ar error range of 100 bp..



All SV Detection tools tested have poor recall of experimentally determined SVs

However, recall of these SVs at the coordinate level was much lower among these tools. Strikingly, SvABA's unfiltered output recall rate was 58% lower!

Error range (+= bps)	# of SVs detected by N tools				
	2	3	4	5	6
0	5029	1070	73	3	0
10	9449	2573	294	5	0
100	20054	5783	862	20	0
1000	59280	17997	4880	456	0

NUMBER OF SVS DELECTED IN LOOIS WITH VALVING margins of allowed bp differences



LIVESTRONG®

Conclusions

- Different published cancer studies have used these tools to identify SVs in exome data
- Given their poor recall rate with established SVs, we question these tools' applicability to WES data.
- A reasonable approach may be considering only SVs detected by more than one tool.
- We identified 5783 SVs to characterize these cell lines.

Limitations

- Lack of coordinate info for known SVs Only evaluated tool with 59 known SVs even
- though each tool identifies 1000s of SVs
- No tool accounted for a specific type of SVs: Copy Number Variants (CNVs)

Future steps

- Calculate structural variant burden for each cell-line's output VCFs
- Characterise CNVs in each MM cell-lines.
- Use characterised SVs to **detect neoantigens**.
- Visualize characterised SVs.
- **Display characterisation** of MM cell-line with an interactive R shiny app.

Acknowledgements

- LiveSTRONG Cancer Institute who inspired and assisted us in our work.
- Peers in the **Big Data in Biology FRI** stream.
- Texas Advanced Computing Center (TACC) for large computing resources to parallelize our analysis.
- **Biomedical Research Computing Facility** (BRCF) for local computing and storage.
- Keats lab at the Translational Genomics **Research Institute** for the sequencing data

References

- Yokoyama, Toshiyuki T., and Masahiro Kasahara. "Visualization Tools For Human Structural Variations Identified By Whole-Genome Sequencing". Journal Of Human Genetics, vol 65, no. 1, 2019, pp. 49-60. Springer Science And Business Media LLC, doi:10.1038/s10038-019-0687-0. • "Exome Sequencing - An Overview | Sciencedirect Topics". Sciencedirect.Com, 2020,
- https://www.sciencedirect.com/topics/neuroscience/exome-sequencing. • "What Are Whole Exome Sequencing And Whole Genome Sequencing?". Genetics Home Reference, 2020, https://ghr.nlm.nih.gov/primer/testing/sequencing.